NCT06332131
Effects of Immune Checkpoint Inhibitors on Coronary Microvasculature
Enrolling by Invitation
Not specifiedAges 18+ObservationalAbramson Cancer Center at Penn MedicineInvestigator-initiated
~25 participants
Updated 2026-02-09 on ClinicalTrials.gov
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of new abnormal myocardial blood flow reserve (MBFR)
Measured over 3 months
Conditions
Where it's being run
1 sites across 1 statesPennsylvania1
Study leadership
- Marielle Scherrer-Crosbie, MD, PhD · PRINCIPAL_INVESTIGATOR · University of Pennsylvania
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
≥18 years of age
Either diagnosis of breast cancer with plan for treatment according to the Keynote 522 regimen or non-small-cell lung cancer planned for neoadjuvant treatment that includes pembrolizumab
Able to provide written informed consent
Exclusion
Pregnant or breast-feeding:
Prior treatment with ICI therapy.
Vulnerable patients, including pregnant women and prisoners
Absolute Contraindication to rest/vasodilator stress PET/CT
What this trial measures
- Incidence of new abnormal myocardial blood flow reserve (MBFR)3 months
Development of MBFR\<2